The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Noxopharm (NOX) publishes preliminary data from its IONIC investigator-initiated pilot trial for its oncology drug Veyonda
  • IONIC is exploring Veyonda’s potential to increase the efficiency of Opdivo, an immune inhibitor used to treat solid tumours
  • The company completed phase one of the trial, with the findings being published ahead of the American Society of Clinical Oncology’s (ASCO) annual meeting
  • Noxopharm is developing its partnerships with researchers to build two new technology platforms, Chroma and Sofra
  • Noxopharm last traded at 4.9 cents at 3:15 pm AEST

Biotech company Noxopharm (NOX) has published preliminary data from its IONIC investigator-initiated pilot trial for oncology drug Veyonda.

IONIC is exploring the Veyonda’s potential to increase the activity of Bristol Myers Squibb’s immune checkpoint inhibitor Opdivo (nivolumab) for patients with solid tumours.

Noxopharm’s phase one results will be published in the form of an abstract at the American Society of Clinical Oncology’s (ASCO) annual meeting, which will take place in Chicago in June.

The annual ASCO meeting is one of the largest gathering of oncology professionals, exposing the trial to an array of industry professionals.

Bristol Myers Squibb and Noxopharm completed the trial under a strategic partnership on 30 patients across six sites in Sydney and regional New South Wales.

Noxopharm will continue to develop novel treatments for cancer and inflammation, including the production of new technology to enhance mRNA vaccines.

The company is partnering with leading researchers to build two new technology platforms Chroma (oncology) and Sofra (Inflammation, autoimmunity and mRNA vaccine enhancements) to advance medical technologies.

NOX last traded at 4.9 cents at 3:15 pm AEST.

NOX by the numbers
More From The Market Online
Image of a woman holding a bottle of hemp oil

Little Green Pharma jumps into distribution with acquisition

Little Green Pharma is aiming to make the strategic acquisition of HH (Australia) Pty Ltd to…
Image of cancer cells

Radiopharm approved to start Lu-RAD202 safety trials, door open for in-human studies

Radiopharm Theranostics has received ethics approval for its trial into Lu-RAD202, a novel treatment for these…
Close up of a nasal spray

LTR Pharma pairs with Men’s Health Downunder for supply of erectile dysfunction spray

LTR Pharma Ltd has signed an agreement with Men's Health Downunder to facilitate supply of its…
Immune system concept ai gen

Immutep dips as safety test for flagship drug IMP761 shows no adverse effects

Immutep has reported a small-scale conceptual safety test among 5 patients using flagship drug IMP761 has…